Skip Navigation LinksHome > June 2014 - Volume 26 - Issue 3 > Recent progress in the utility of anti-Müllerian hormone in...
Current Opinion in Obstetrics & Gynecology:
doi: 10.1097/GCO.0000000000000068
FERTILITY: Edited by Aydin Arici

Recent progress in the utility of anti-Müllerian hormone in female infertility

Grynnerup, Anna G.-A.a,b; Lindhard, Anettea; Sørensen, Steenb

Collapse Box

Abstract

Purpose of review

To discuss the recent developments in the utility of anti-Müllerian hormone (AMH) in the context of female infertility.

Recent findings

AMH measurements have entered the clinical practice in counseling of women before in-vitro fertilization (IVF) treatment. AMH measurements can predict both poor and hyperresponse, and can enable clinicians to individualize the treatment strategies. In natural conception, AMH is a good predictor of age at menopause, but it is unclear whether AMH correlates with the fecund ability in the normal population. AMH has also proven its utility in the assessment of ovarian damage due to gonadotoxic treatment or ovarian surgery. Lastly, AMH might assist in the initial diagnosis of oligomenorrhea or amenorrhea, as high levels of AMH are suggestive of polycystic ovarian syndrome and seem to correlate with the severity of the syndrome.

Summary

AMH is a glycoprotein secreted by the granulosa cells of small growing follicles and indirectly reflects the primordial follicle pool. The ovaries contain a limited number of primordial follicles and their depletion marks the menopause. Thus, the remaining primordial follicle pool is referred to as the ovarian reserve. The clearest data for the clinical utility of AMH is in the context of IVF. The support for other indications is weaker, but rapidly increasing.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.